<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Jason Amartey on Medium]]></title>
        <description><![CDATA[Stories by Jason Amartey on Medium]]></description>
        <link>https://medium.com/@jasonoamartey?source=rss-48d749182bd1------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*GYQEmKSGjxPqGm0Vvhsx7w.jpeg</url>
            <title>Stories by Jason Amartey on Medium</title>
            <link>https://medium.com/@jasonoamartey?source=rss-48d749182bd1------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 07:36:01 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@jasonoamartey/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Unlocking Potential: Why Venture Capital Should Fuel Africa’s Biotechnology Ecosystem]]></title>
            <link>https://medium.com/included-vc/unlocking-potential-why-venture-capital-should-fuel-africas-biotechnology-ecosystem-185daa4ef9c7?source=rss-48d749182bd1------2</link>
            <guid isPermaLink="false">https://medium.com/p/185daa4ef9c7</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[africa]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[research-and-development]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Jason Amartey]]></dc:creator>
            <pubDate>Sat, 14 Dec 2024 21:16:46 GMT</pubDate>
            <atom:updated>2024-12-14T21:16:46.986Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>👉🏿 TL;DR</strong></p><p>🌍 The African continent, despite its vast population, does not boast a huge amount of Biotechnology companies, which can be attributed to educational, and infrastructural challenges.</p><p>🏦Venture Capital investments in Africa are dominated by Fintech and Energy Sectors.</p><p>🧬 The Biotechnology Ecosystem can be unlocked by fostering incubators, accelerators, and research institutions that support innovation.</p><p>🔗 Collaboration between Academia, Industry, and Government should be facilitated as well as advocating for policies that create a favourable regulatory environment for Biotechnology entrepreneurship and investment.</p><p><strong>Introduction</strong></p><p>In this deep dive, I will aim to answer the question, “Can Venture Capital be used to drive the Biotechnology ecosystem in Africa?” I will explore the current landscape of Biotechnology companies in Africa, identify which funds are already investing in African Biotech, and examine the factors that encourage or hinder investment in this sector.</p><p>Before we get started, it is important to clarify what is meant by Biotech, as it can sometimes be confused with HealthTech, MedTech, or Pharma. Since all these areas can be referred to as the broader life science sector, it can be easy to confuse what they are.</p><p><strong>🛠️What is MedTech?</strong></p><p>Companies working in the MedTech field tend to produce devices, tools, software and machines. These are usually made to monitor, diagnose, treat or care for people’s health. Medtech products are typically used within hospitals and clinics by specialists or doctors and tend to be regulated. Examples of Medtech include surgical robots, augmented reality systems for surgeons and exoskeletons.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*XFf3coLazmTRisQl" /><figcaption>Photo by <a href="https://unsplash.com/@quangtri?utm_source=medium&amp;utm_medium=referral">Quang Tri NGUYEN</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p><strong>⌚️What is HealthTech?</strong></p><p>HealthTech focuses on personal health, by providing individuals with the tools to manage their health as opposed to MedTech which provides tools for professionals to diagnose and treat patients. Companies in this sector develop products that make it easier to get care or monitor one’s health such as apps and wearables. HealthTech products are usually used outside of hospital walls and aren’t regulated to the same extent as other life-science areas. Examples of HealthTech include the Apple Watch, Whoop Band or the Oura Ring.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*RI2LUYvDcWM6NDkL" /><figcaption>Photo by <a href="https://unsplash.com/@andresurena?utm_source=medium&amp;utm_medium=referral">Andres Urena</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p><strong>💊 What is Pharma?</strong></p><p>Pharma or pharmaceutical companies put simply, develop medicines, often using synthetic components. The process can take many years, as it’s a highly regulated field requiring extensive research and development before a product can finally reach the market.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*TlBVjoyR8rDtMOZa" /><figcaption>Photo by <a href="https://unsplash.com/@freestocks?utm_source=medium&amp;utm_medium=referral">freestocks</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p><strong>🧬 What is Biotechnology?</strong></p><p>As the name implies, Biotech is built on biology. Companies in this sector usually research and make products for medical or agricultural purposes. In other words, products can range from crops that avoid pests to next-generation drugs of the biopharma variety. Biotech products end up in places such as pharmacies or laboratories and are highly regulated.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*VRkXGStky4MUL-D3J-bOWw.png" /></figure><p><em>Comparison between life science sub-sectors: sectors differ in use, regulation and types of technology used.</em></p><p><strong>Landscape of the Biotech Industry in Africa</strong></p><p>Now that we have clarified what Biotech is, the next question to ask is: What is the current state of the Biotech industry in Africa?</p><p>The African continent, despite its vast population — nearly twice that of Europe and about 2.5 times that of North America — does not have the same number of Biotech companies as those regions. This disparity can be attributed to a variety of factors, many of which are deeply rooted in the continent’s economic, educational, and infrastructural landscapes.</p><p>One of the primary reasons for this gap is the strength of academic and research institutions in North America and Europe. These regions are home to some of the world’s most advanced universities and research centres, which consistently produce groundbreaking scientific discoveries. Strong academic ecosystems create fertile ground for spinouts, the commercialisation of research into Biotech startups, and sustained innovation. In these regions, funding opportunities are abundant, whether through government grants, venture capital, or private investment, all of which are crucial for turning academic research into market-ready Biotech products.</p><p>In contrast, many African countries are still in the process of building or strengthening their research infrastructures. There are pockets of Africa where innovation is abundant, in places such as South Africa, Kenya, and Nigeria, Biotech research is slowly gaining momentum. There is a lack of consistent funding for research, limited access to advanced technology, and the absence of a robust network of incubators and accelerators that support Biotech startups which further hinders the growth of the industry.</p><p>A broader challenge lies in the inconsistency of funding for research that addresses Africa-specific issues. Africa contributes only 1–2% of global research despite representing about 18% of the world’s population. The continent’s research and development (R&amp;D) investment remains low, at just 0.42% of GDP — well below the global average of 1.7%. South Africa is the country in Africa that spends the highest percentage of its GDP on research and development and that is still only at 0.6%, far from the global average. Compare that with a country like Israel which is well known for being an innovative hub spends about 6% of its GDP on R&amp;D demonstrating a correlation between innovation and the amount spent on R&amp;D.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vvTUKNyVLxbTIY-RIFkW9Q.png" /></figure><p><em>South Africa spends the highest percentage of its GDP on R&amp;D (0.6%) which is still fairly below the 1.7% global average</em></p><p>Another contributing factor is the availability of talent. In regions like North America and Europe, there is a well-established pipeline of highly skilled professionals with expertise in life sciences, technology, and entrepreneurship. These professionals often collaborate across sectors, forming interdisciplinary teams that are essential in driving Biotech innovation forward. In Africa, while there is a wealth of young talent, the opportunities for specialised training and development in Biotech are still emerging. Regulatory environments in North America and Europe are more established and supportive of Biotech innovation. These regions have clear frameworks for clinical trials, patent protections, and approval processes for new drugs and treatments, which encourage investment and provide certainty for companies operating in the space. In contrast, many African nations are still developing regulatory frameworks that can accommodate the unique challenges and opportunities presented by Biotech innovations, particularly in the areas of healthcare, agriculture, and environmental sustainability.</p><p>Despite these challenges, there is immense potential for Biotech in Africa. The continent faces many pressing challenges — such as food security, public health crises, and environmental degradation — that Biotech can help address. There are also growing efforts to harness indigenous knowledge and biodiversity in developing unique solutions that are tailored to the continent’s needs. With continued investment in education, research, and infrastructure, and the development of a supportive regulatory environment, Africa’s Biotech sector could experience significant growth in the coming years. Examples of Biotech companies in Africa that have successfully raised venture capital funds include AzarGen Biotechnology, Yemaachi Biotech, 3X4Genetics, and 54Gene.</p><p><strong>AzarGen Biotechnologies</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/395/1*FEOmxPXF2ugs8wk139tq0A.png" /></figure><p>AzarGen Biotechnologies is a South African Biotechnology company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants, their lead candidate is expected to increase the survivability of premature-born infants in the developing world at a lower cost. The South African company has raised $3.1M in series B funding from Cape Venture Partners and Industrial Development Corporation of South Africa.</p><p><strong>Yemaachi Biotechnology</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/447/1*MZCm-hy3MoO9I1BlodwvcQ.png" /></figure><p>Yeemachi is part of a new wave of African Biotech firms striving to address some of the continent’s most pressing challenges through innovative solutions in life sciences. On their website, Yemaachi claims to be “<strong>Cancer innovation shaped by Africa — for the world,</strong> <em>Yemaachi is creating and harnessing the world’s most robust cancer knowledge base to develop the next generation of cancer drugs that are effective in diverse populations.”</em></p><p>Yemaachi is backed by some of the biggest players in the space such as Y Combinator, AAIC Investment and V8 Capital Partners as well as partnering up with institutes such as the Bill and Melinda Gates Foundation, Science for Africa and LifeArc.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/902/1*6IudwbfMeZK4OumsWSS3hA.png" /><figcaption><em>Source: Yemaachi</em></figcaption></figure><p><strong>3X4Genetics</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/571/1*EGLJ582BR6_tDHrrGzewxg.jpeg" /></figure><p>3x4Genetics is a South African Biotech company that combines genetics and nutrigenomics to help people live longer and healthier.</p><p>On their website, it is stated “<em>We’re a genetics-based health technology company that combines advanced genetic testing, nutrigenomic education, and a global network of accredited practitioners to help people make sound, daily choices to live longer, healthier, and better lives.”</em></p><p>3X4Genetics raised $2.5M in a Series A round from Alethea Capital Management and HAVAÍC.</p><p><strong>54Gene</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/318/1*TuBQL_j7fZKuVSu57OLHGQ.png" /></figure><p>54Gene is certainly an interesting one; it was once a Nigerian genomics company that made headlines when it raised $45M in VC investment in 2 years across 3 funding rounds. The genomics startup has been considered the showpiece of Africa’s fledging Biotech space since it was accepted into the Y Combinator cohort in 2019. The company stated its mission was addressing the need to include under-represented African genomic data in research, which could subsequently lead to medical breakthroughs and new healthcare solutions worldwide. The aim was to understand the genetic impact on disease penetrance and risk in Africans to develop better diagnostic and risk assessment tests that would inform a more targeted approach to healthcare.</p><p>Just as quickly as it rose, 54Gene started to falter, the Biotech went through a massive growth phase to accommodate the opportunity of being one of the largest Covid test providers in Nigeria. However, after raising a large amount of capital, a $15M Series A that year and a $25M Series B in 2021 from investors including Adjuvant Capital, Cathay AfricInvest Innovation Fund (CAIF), KdT Ventures and Endeavor Catalyst, the Biotech started to have to have trouble in 2022 where revenues massively decreased and had to lay off the majority of its employees as well turnover of its executive team, the company is said to have gone in liquidation in 2023 and permanently shut down in July 2024. According to <a href="https://techcabal.com/2023/09/27/54gene-shutting-down-operations/">Techcabal</a>, 54Gene’s failure will have consequences. “When one of the biggest flagship companies that have raised the most money in a sector has its value collapse overnight, global investors will hesitate about funding the sector.” This rapid decline of an African Biotech will undoubtedly have a ripple effect on Venture Capital investment in the region.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*RnTUT_pIK-BF2XNNENh4dg.png" /></figure><p><em>Notable Biotech companies in Africa include 54gene, Yemaachi and 3x4Genetics.</em></p><p><strong>Why is it difficult to invest in Biotechnology companies in Africa?</strong></p><p>As mentioned earlier, investing in African Biotech faces multiple challenges, primarily due to infrastructure limitations, financial constraints, brain drain, and regulatory gaps. This means there are no successful exits which gives an example of why more funds should be invested in the African continent.</p><p>African Biotech development is hampered by insufficient infrastructure, including poorly equipped labs, a lack of specialised facilities like greenhouses, and unreliable power. Without adequate facilities, collaboration with international research organizations also suffers, limiting access to global networks and knowledge exchange. This limits innovation and drives skilled researchers to seek opportunities in countries with better resources, contributing to a brain drain.</p><p>The African Biotech sector faces a shortage of skilled professionals due to brain drain Many researchers leave for countries (typically Europe and North America) offering better pay, facilities, and career growth. In Nigeria in particular, this is known as “Japa”. It has become a popular trend among the youth, who are seeking better opportunities abroad. Africa’s challenges in science and technology also include limited funding, low literacy rates, and gender inequality in scientific fields. This skills gap stifles the region’s ability to drive Biotech advancements independently, limiting the development and transfer of essential technologies.</p><p>Funding is a major hurdle for African Biotech. Government funding is often limited because resources are focused on critical areas like poverty reduction, healthcare, and education. This pushes researchers to rely on foreign donors, which introduces challenges.</p><p>Weak policies and ineffective regulatory frameworks also restrict Biotech growth in Africa. In some cases, the regulatory environment is inadequate, with missing or poorly enforced policies for Biotech research and commercialization. Corruption, lack of institutional capacity, and insufficient political will further hinder regulatory progress. As a result, critical projects face delays or are halted entirely, impacting food security and healthcare potential.</p><p><strong>💰What are the Industries That See the Most Investment in the Region?</strong></p><p>Since Biotech isn’t the most attractive sector for venture capital on the African continent, the question is which sectors are?</p><p>FinTech consistently emerges as one of the most appealing sectors for venture capital and remains a key focus in Africa’s VC landscape. In 2023, FinTech attracted around $1.2 billion in investments, accounting for nearly 50% of the total investments on the continent. The opportunity in FinTech is largely driven by Africa’s low financial inclusion rates. With less than 25% of Africans having access to credit and under 50% holding formal bank accounts, FinTech presents a significant opportunity for disruption. The demand for innovative solutions in digital payments, lending, and financial services continues to fuel investor interest in Africa.</p><p>Another sector gaining momentum is ClimateTech/Energy which includes investments in climate-related and renewable energy technologies. In 2023, ClimateTech secured approximately $800 million in funding, representing close to one-third of total VC investments in Africa. The rise in climate-related investments aligns with the growing trend of impact investing, as investors increasingly prioritise solutions that address both environmental challenges and sustainable development goals. The renewable energy sector, in particular, is expected to expand, driven by Africa’s urgent need for affordable, clean energy solutions and a global shift toward sustainability.</p><p>Biotech can sit in both the Healthcare and Agriculture and Food sectors with each receiving $190 million and $180 million in funding respectively, (almost 10% of investment in FinTech each) which accounted for 7% of total VC investments in Africa.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*nd7i-s9_1yJLf25KxFdX-Q.png" /></figure><p><em>FinTech start-ups received nearly half of investments in 2023 followed by Energy/ClimateTech start-ups with over 30% of investments, healthcare and agriculture &amp; food only received 7% each of investments.</em></p><p>With such enormous funding going into FinTech companies, it is no mystery why the majority of Africa’s high-value start-ups are FinTech companies. As of November 2024, Africa boasts only eight companies with a valuation of $1 billion or higher, commonly referred to as “unicorns.”. Seven out of the eight unicorns are FinTech companies, illustrating how financial technology seems to be the driver of innovation on the continent. Startups in this sector have seen substantial growth due to the continent’s young, tech-savvy population. The relatively low levels of financial infrastructure in many African nations have provided fertile ground for FinTech companies to disrupt traditional models and rapidly scale. The sole exception on the African unicorn list is Andela which is a talent marketplace.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*A9JZ4F9I9fuh9riQYeHykA.png" /></figure><p><em>As of November 2024, there are only 8 startups that have been valued at $1B or higher, 7 out of the 8 unicorns are FinTech, whilst one is a talent marketplace, 6/8 were founded in Nigeria with the remaining 2 being founded in Egypt and Senegal.</em></p><p><strong>💸 WhichFunds are Investing in Biotechnology Companies in Africa?</strong></p><p>Currently, there is a notable lack of VC companies that are investing in Biotech companies on the African continent, however, there are many that are focused on investing in healthcare and life sciences altogether, these include Villgro Africa, Investment Funds for Health Africa, HealthCap, i3 Initiative and Kepple Africa Ventures.</p><p><strong>HealthCap Africa</strong></p><p>HealthCap, led by Ola Brown, is an Africa-focused investment firm dedicated to improving the lives of 1.4 billion Africans by investing in ventures that contribute to a healthier world. Their portfolio boasts nearly 20 companies valued at over $750m including Koniku, a synthetic Biotechnology company that is leveraging synthetic biology merged with silicon to build devices to map all volatile organic compounds that touch human life.</p><p><strong>Villgro Africa</strong></p><p>Villgro Africa is an incubator and impact investor that supports emerging healthcare businesses in Africa, predominantly in East Africa (Kenya, Uganda, Zambia, and Ethiopia).</p><p><strong>Investing in innovation (i3) Africa</strong></p><p>i3 is a pan-African initiative to support promising, early &amp; growth-stage Healthcare companies in Africa. The fund is backed by The Bill &amp; Melinda Gates Foundation, and it aims to empower startups to bring high-quality health products closer to patients. The i3 Initiative has unveiled a $7 million fund that it intends to distribute between 30 health companies that qualify for its cohort.</p><p><strong>Kepple Africa Ventures</strong></p><p>Kepple Africa Ventures Kepple Africa is a venture capital company enabling the development of innovative technology in Africa. It connects startups with investors and strategic corporate partners to facilitate cross-border expansion and facilitates mergers.</p><p>Kepple Africa invests in startups across many sectors, but it invests in the life sciences sector. Its portfolio includes several notable health tech companies</p><p>It is worth mentioning that these investors are typically focused on health as a whole rather than just Biotech companies. This shows there is a real need for VCs to invest in the Biotech space.</p><p><strong>How Can We Improve Biotechnology Investment in Africa?</strong></p><p>Although FinTech has dominated Africa’s venture capital landscape, the Biotech sector holds immense potential for transformative impact. By addressing specific challenges and leveraging unique opportunities, Africa’s Biotech industry can be unlocked.</p><p>To achieve this, it is crucial to support the growth of local venture capital firms and fund managers who understand the distinctive challenges and opportunities of African markets. Aligning Biotech investments with key Sustainable Development Goals such as healthcare, agriculture, and environmental sustainability is essential, along with developing standardised metrics to track and communicate the social and environmental impact of Biotech ventures.</p><p>Proving success is key to attracting further investment. Demonstrating that African Biotech companies can achieve successful exits, through Initial Public Offerings (IPOs), mergers and acquisitions, or strategic partnerships — will validate the Biotech ecosystem and draw more investors. Alternative exit strategies such as licensing deals and joint ventures can also maximize returns, showing venture capitalists that Biotechnology investments in Africa can thrive.</p><p>Leveraging local expertise is critical to navigating complex regulatory landscapes and cultural nuances. A phased investment approach, with staged funding, can help minimize risk and optimize capital allocation. Partnering with Development Finance Institutions (DFIs) to access patient capital will also enhance credibility.</p><p>Strengthening the Biotech ecosystem is vital. This can be done by fostering incubators, accelerators, and research institutions that support innovation, facilitating collaboration between academia, industry, and government, and advocating for policies that create a favourable regulatory environment for Biotech entrepreneurship and investment.</p><p><strong>⌛️ Conclusion</strong></p><p>Africa’s rich biodiversity and human capital are some of its most valuable assets. To fully harness this potential, Africa needs to shift to being a producer of scientific knowledge and innovation. The biotech sector in Africa holds promise to drive this transformation, opening up employment opportunities for Africa’s young population and driving economic growth across the continent.</p><p>As one of the most biodiverse regions in the world, Africa is home to unique plant species and ecosystems. With the right investment and strategic direction, its potential in Biotechnology can finally be unlocked.</p><p>Thank you for reading my Deep Dive on the African Biotechnology Ecosystem. Please feel free to reach out to me on <a href="https://www.linkedin.com/in/jasonamartey/">LinkedIn</a> if you feel there’s anything I missed or could be added or you just want to discuss further</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=185daa4ef9c7" width="1" height="1" alt=""><hr><p><a href="https://medium.com/included-vc/unlocking-potential-why-venture-capital-should-fuel-africas-biotechnology-ecosystem-185daa4ef9c7">🔓Unlocking Potential: Why Venture Capital Should Fuel Africa’s Biotechnology Ecosystem</a> was originally published in <a href="https://medium.com/included-vc">Included VC</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>